by The global Transthyretin Amyloid Cardiomyopathy Treatment Market is estimated to be valued at US$ 1687.23 Mn in 2023 and is expected to exhibit a CAGR of 31% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Transthyretin amyloid cardiomyopathy (ATTR-CM), previously known as senile systemic amyloidosis (SSA), is caused by deposition of misfolded transthyretin protein fibrils in the heart. Symptoms include shortness of breath, fatigue, irregular heartbeat. Currently approved drugs include tafamidis and inotersen. Tafamidis stabilizes the transthyretin tetramer and prevents the formation and progression of amyloid fibrils. Inotersen is a RNA-based therapeutic that inhibits transthyretin production in the liver. Pipeline drugs aim to provide safer and more efficacious options for treatment and management of ATTR-CM through novel mechanisms of action.
Market key trends:
One of the key trends in the Transthyretin Amyloid Cardiomyopathy Treatment Market is rising research & development for novel therapeutic targets. Several biotech companies are researching antisense oligonucleotides, RNA interference therapeutics, gene editing tools and immunotherapy approaches to block production of pathogenic transthyretin protein or promote clearance of amyloid deposits. For instance, Alnylam Pharmaceuticals is developing patisiran, an RNAi therapeutic targeting transthyretin for treatment of ATTR amyloidosis. Another trend is increasing collaborations between industry players to accelerate drug development. In April 2021, Pfizer Inc. collaborated with Alnylam Pharmaceuticals to develop RNAi therapies for ATTR amyloidosis. Such partnerships help join scientific and development expertise to address high unmet needs in this market.
Porter’s Analysis
Threat of new entrants: The transthyretin amyloid cardiomyopathy treatment market exhibits high entry barriers due to high costs associated with clinical trials and stringent regulatory requirements.
Bargaining power of buyers: The bargaining power of buyers is moderate due to the niche nature of the condition and the lack of adequate treatment substitutes.
Bargaining power of suppliers: Pharmaceutical companies that develop new treatment options hold significant bargaining power over buyers in this market.
Threat of new substitutes: The threat is low currently due to lack of new therapeutic substitutes for TTR amyloid cardiomyopathy in the pipeline.
Competitive rivalry: High as key players compete to develop new mechanisms of action for safer and more effective treatment options.
Key Takeaways
The Global Transthyretin Amyloid Cardiomyopathy Treatment Market Size is expected to witness high growth, exhibiting CAGR of 31.% over the forecast period, due to increasing R&D investments from players and rising awareness about the disease.
North America is expected to dominate the global market during the forecast period owing to high prevalence of TTR amyloidosis and early adoption of advanced treatment options in the region. However, Asia Pacific is likely to exhibit the fastest growth over the coming years due to rising geriatric population, increasing healthcare expenditure, and growing focus of key players in countries such as China and India.
Key players operating in the transthyretin amyloid cardiomyopathy treatment market are Pfizer Inc., GlaxoSmithKline Plc., Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc. Major players are focusing on developing RNAi-based therapies, gene silencing strategies, and small molecule approaches to treat TTR amyloid cardiomyopathy.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
